WASHINGTON (AP) — A second-line drug to treat a life-threatening form of leukemia has won federal approval, the Food and Drug Administration said Monday.

Tasigna, known generically as nilotinib, won approval to treat chronic and accelerated phase Philadelphia chromosome-positive, chronic myeloid leukemia. The form of the blood cancer affects about 4,500 Americans a year.